GlycoT was awarded a Phase I SBIR titled “Development of a facile, robust, scalable, and versatile chemoenzymatic glycan-remodeling approach for site-specific antibody conjugation” (1/R43GM146537) with total funding support of $321,239.
Read the full article at: www.glycot.com
